Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics shares are up 27% over the past month (around $40), as the clinical-stage biotech advances VK2735, a dual GLP-1/GIP candidate, with two Phase 3 studies expected to read out in 12–18 months. A subcutaneous VK2735 Phase 3 catalyst is framed as potentially binary—strong results could drive a move toward the article’s $100 target by end-2027, while disappointing data would likely be sharply negative. The company also seeks weight-maintenance benefits via a dosing/frequency study and launched a Phase 1 program for an amylin/calcitonin pathway drug, adding upside but not eliminating the high-risk, no-products-yet profile.

Analysis

VKTX is still a probability-weighted call option on the obesity franchise, not an earnings story. The recent run likely brought forward some of the late-stage success premium, so the next leg higher requires data, not just enthusiasm; absent a partner deal or a materially better efficacy/tolerability profile, the stock can drift on dilution fears and trial-timing slippage.

The real competitive signal is broader than one small-cap name: a strong readout would tighten the bar for every single-asset obesity developer and could force capital toward the incumbents with manufacturing scale, payer access, and commercial infrastructure. If the maintenance and oral programs work, the value shifts from peak efficacy to durability and convenience, which is where the bigger metabolic franchises monetize best. If they disappoint, it reinforces that obesity is an execution business and makes the market more willing to pay for diversified platforms like LLY/NVO rather than pre-revenue challengers.

The key risk over 6-18 months is financing. Phase 3 burn plus multiple programs raises the odds of equity issuance into strength, which can cap upside even with decent data. The thesis is falsified by any safety/tolerability issue, inferior durability versus current standards, or a capital raise before the main readout. Near term, this is mostly a sentiment trade; the catalyst path is months, not days.

Key Decisions for Investors

• Do not chase VKTX common after the recent rerating; wait for a pullback or a broader biotech selloff before initiating any exposure.
• If expressing upside, use a limited-risk 12-18 month call spread in VKTX rather than stock, because the upside is binary and dilution risk can cap equity returns.
• Prefer LLY or NVO over VKTX for obesity exposure if the objective is lower event risk; these names monetize the market today while VKTX still depends on clinical conversion.
• Use XBI as a hedge if long VKTX into catalyst windows; this isolates idiosyncratic readout risk and reduces beta bleed from a weak biotech tape.
• Set an alert for any secondary offering or updated cash-burn guidance; that would be the first sign the market is underestimating financing risk and should reduce or exit VKTX exposure.